AVEO AVEO Pharmaceuticals Inc

$0.17 (3.99%)

AVEO Stock Analysis Overview

What this means: InvestorsObserver gives AVEO Pharmaceuticals Inc (AVEO) an overall rank of 42, which is below average. AVEO Pharmaceuticals Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 42 means that 58% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

AVEO Pharmaceuticals Inc (AVEO) Analyst Forecast

Next 12 months ➝Current Price$4.4352-week High$11.2052-week Low$2.23MEAN$20.67+366.50%HIGH$26.00+486.91%LOW$12.00+170.88%
  • Last Price$4.43
  • Previous Close$4.26
  • Change $0.17
  • Open$4.30
  • Volume251,821
  • Avg. Volume (100-day)694,544
  • Market Capitalization$114M
  • Days Range $4.25 - $4.46
  • 52-week Range $2.23 - $11.20
  • Dividend Yield
  • Ex. Dividend Date
  • P-E
  • EPS-0.01
  • Earnings Date08/13/2020
  • SectorHealthcare
  • IndustryBiotechnology
  • Avg. Analyst Rec.
  • Beta0.003
  • PEG Ratio
AVEO Pharmaceuticals Inc is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need. The Company's aim is to retain North American rights to its oncology portfolio while securing partners in development and commercialization outside of North America. It is seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for advanced or metastatic renal cell carcinoma (RCC). It has outlicensed tivozanib (FOTIVDA) for oncology in Europe and other territories outside North America.